Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T18:04:26.148Z.
Calculation as of: 2026-10-06T18:04:26.148Z.
Quote observation: 2026-10-06T18:00:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4ee4545eb4fe5103374f291c717036760539f0ddea1c9b76c24efb1a2679ece0
EARNINGS YIELD
N/A
Odyssey Therapeutics, Inc.
Market Cap
$901.55M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$913.78M
Earnings Yield
2.29%
TTM Avg
2.73%
3Y Avg
2.26%
5Y Avg
1.85%
Market Cap
$927.47M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$877.52M
Earnings Yield
17.57%
TTM Avg
17.36%
3Y Avg
17.36%
5Y Avg
17.36%
Market Cap
$946.27M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$868.65M
Earnings Yield
N/A
TTM Avg
2.57%
3Y Avg
2.57%
5Y Avg
2.57%
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Odyssey Therapeutics, Inc. (ODTX) | $901.55M | N/A | N/A | N/A | N/A |
| HealthStream, Inc. (HSTM)vs › | $913.78M | 2.29% | 2.73% | 2.26% | 1.85% |
| Bioventus Inc. (BVS)vs › | $899.02M | 5.80% | 3.29% | 3.29% | 3.62% |
| MoonLake Immunotherapeutics (MLTX)vs › | $927.47M | N/A | N/A | N/A | N/A |
| CeriBell, Inc. (CBLL)vs › | $932.06M | N/A | N/A | N/A | N/A |
| Kura Oncology, Inc. (KURA)vs › | $939.11M | N/A | N/A | N/A | N/A |
| Arbutus Biopharma Corp (ABUS)vs › | $877.52M | 17.57% | 17.36% | 17.36% | 17.36% |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $946.27M | N/A | N/A | N/A | N/A |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $868.65M | N/A | 2.57% | 2.57% | 2.57% |
| Savara Inc. (SVRA)vs › | $948.81M | N/A | N/A | N/A | N/A |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute